[Skip to Navigation]
Comment & Response
December 2016

Oral Fluoroquinolone Use and Retinal Detachment—Reply

Author Affiliations
  • 1Department of Epidemiology of Health Products, The French National Agency for Medicines and Health Products Safety, Saint-Denis, France
JAMA Ophthalmol. 2016;134(12):1448-1449. doi:10.1001/jamaophthalmol.2016.3479

In Reply Our main analysis focused on the immediate acute effects of fluoroquinolones. Therefore, as is usually done, we excluded patients exposed during the intermediate risk period. Because the intermediate risk period is not associated with an increased risk, this exclusion is unlikely to have affected the odds ratio. Individuals with a fluoroquinolone prescription during the 10 days preceding retinal detachment (RD) and exposed during the intermediate risk period (ie, during the 50 prior days) were not considered exposed during the risk period. Consistently, individuals with 2 fluoroquinolone prescriptions dispensed within 50 days in the control period were not considered exposed either.

Add or change institution